Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN OVARIAN PARP 100: avelumab + chemotherapy followed by avelumab + talazoparib vs bevacizumab + chemotherapy in advanced ovarian cancer
jRCT2080224502Phase 3Completed
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of avelumab and talazoparib in Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms). Started Jan 2019; status: completed.
02
Drugs
avelumabtalazoparib
03
Conditions
Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2080224502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224502.